- Home
- TNYA
as 11-18-2025 3:41pm EST
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 326.0M | IPO Year: | 2021 |
| Target Price: | $8.60 | AVG Volume (30 days): | 3.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.36 - $4.01 | Next Earning Date: | 11-10-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Tenaya Therapeutics Inc. (TNYA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Tingley Whittemore | TNYA | Chief Medical Officer | Nov 17 '25 | Sell | $1.33 | 2,877 | $3,826.41 | 169,926 | |
| Ali Faraz | TNYA | Chief Executive Officer | Nov 17 '25 | Sell | $1.33 | 3,126 | $4,157.58 | 299,666 | |
| Higa Tomohiro | TNYA | SVP, Finance | Nov 17 '25 | Sell | $1.33 | 1,367 | $1,818.11 | 93,971 |
Latest Tenaya Therapeutics Inc. News
TNYA Breaking Stock News: Dive into TNYA Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
10 days ago
Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
GlobeNewswire
14 days ago
Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025
GlobeNewswire
a month ago
Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
Simply Wall St.
a month ago
Can Tenaya Therapeutics’ Leadership Messaging Shape Long-Term Perceptions and Value Creation for TNYA?
GlobeNewswire
6 months ago
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
6 months ago
Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting
Simply Wall St.
6 months ago
We're A Little Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate
Compare TNYA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TNYA Tenaya Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.